Liver fibrosis in 102 chronic hepatitis B patients with hepatic steatosis

( views:280, downloads:0 )
Author:
SHI Jun-ping(Department of Hepatology, Hangzhou Sixth People's Hospital, Zhejiang Chinese Medical University, Hangzhou 310014, China)
FAN Jian-gao()
WU Rui()
ZHANG Li()
XUN Yun-hao(Department of Hepatology, Hangzhou Sixth People's Hospital, Zhejiang Chinese Medical University, Hangzhou 310014, China)
LOU Guo-qiang(Department of Hepatology, Hangzhou Sixth People's Hospital, Zhejiang Chinese Medical University, Hangzhou 310014, China)
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 1, Issue 02, 2008
DOI:
Key Word:
Chronic hepatitis B;Fatty liver;Liver fibrosis;Intlammation

Abstract: Objective To evaluate the prevalence of hepatic steatosis in patients with chronic hepatitis B (CHB) and the impact of hepatic steatosis on the progress of fibrosis. Methods Five hundred and sixty two untreated CHB patients (405 males and 157 females) with an average age of 31.3 underwent liver biopsy from January to August 2007. On the day of liver biopsy, a questionnaire was completed and a blood sample was obtained for laboratory analysis. The degree of liver steatosis, necroinflammation and fibrosis was assessed; demographic information and clinical data including age, gender, body mass index (BMI), history of diabetes mellitus, hypertension, dyslipidemia, and HBeAg status, HBV DNA viral load were documented. Results In 562 patients, 102 (18. 2% ) had steatosis. Multivariate analysis demonstrated that liver steatosis was associated with the levels of TG, APO-B, UA, FSG, and higher BMI; and the progress of fibrosis was associated with high degree of hepatic steatosis and necroinflammation, age over 35 years, HBV DNA > 103 copies/L, high BMI and GGT. Conclusions The results show that obesity and dyslipidemia in CHB patients are associated with the hepatic steatosis, and the latter seems to be an important determinant for fibrosis.

  • [1]Soresi M,Tripi S,Franco V,et al.Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.Liver Int,2006,26(9):1119-1125.
  • [2]Bondini S,Younossi ZM.Non-alcoholic fatty liver disease and hepatitis C infection.Minerva Gastroenterol Dietol,2006,52 (2):135-143.
  • [3]Thomopoulos KC,Arvaniti V,Tsamantss AC,et al.Prevalence of liver steatnsis in patients with chronic hepatitis B:a study of associated factors and of relationship with fibrosis.Eur J Gastroenteroi Hepatol,2006,18(3):233-237.
  • [4]Altlparmak E,Koklu S.Yalinkilic M.et al.Viral and host causes of fatty liver in chronic hepatitis B.World J Gastroenterol,2005,11 (20):3056-3059.
  • [5]Gordon A,McLean CA,Pedersen JS,et al.Hepatic steatesis in chronic hepatitis B and C:predictors,distribution and effect an fibrosis.J Hepatol,2005,43(1):38-44.
  • [6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B.Zhonghua Chuamranbing Zazhi,2005,23(6):421-431.中华医学会肝病分会、感染病学分会.慢性乙型肝炎防治指南.中华传染病杂志,2005,23(6):421-431.
  • [7]WHO.Definition,diagnosis and classification of diabetes mellitus and its complications:report u WHO consultation.Geneva:WHO,1999.
  • [8]Guidelines Subcommittee.1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.J Hypertens,1999,17 (2):151-183.
  • [9]Dyslipidemia Study Group of the Chinese Carcliol Association.Recommendation on prevention and cure of dyslipidemia.Zhonghua Xinxueguanbing Zazhi,1997,25(3):169-173.血脂异常防治专题组.血脂异常防治建议.中华心血管病杂志,1997,25(3):169-173.
  • [10]Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association.Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases.Zhanghua Ganzangbing Zazhi,2006,14(3):161-163.中华肝脏病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14(3):161-163.
  • [11]Wang TL,Liu X,Zhou YP,et al.A semiquantitative scoring system for assessment of hepatic inflammation and fibrosis in chronic viral hepatitis.Zhonghua Ganzangbing Zazhi,1998,6 (4):195-197.王泰龄,刘霞,周元平,等.慢性肝炎炎症活动度及肝组织纤维化程度计分方案.中华肝脏病杂志,1998,6(4):195-197.
  • [12]Schiff ER,Sorell MF,Maddrey WC.Disease of the Liver.6 th ed.Philedelphia:Lippincot-Williams and Wilkins,1999:1185-1197.
  • [13]Gramlich T,Kleiner DE,McCullongh AJ,et al.Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.Hum Pathol,2004,35(2):196-199.
  • [14]Powell EE,Jnnsson JR,Clouston AD.Steatosis as a co-factor for other diseases.Hepatology,2005,42(1):5-13.
  • [15]Thomopoulos KC,Theocharis GJ,Teamantns AC,et al.Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.Eur J Gastroenterol Hepatol,2005,17(2):149-153.
  • [16]Cindoruk M,Karakan T,Unal S.Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection.J Clin Gnstroenteroi,2007,41(5):513-517.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn